

Edgar Filing: Bellerophon Therapeutics, Inc. - Form 8-K

Bellerophon Therapeutics, Inc.  
Form 8-K  
March 21, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 21, 2016

Bellerophon Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

|                                                   |                             |
|---------------------------------------------------|-----------------------------|
| Delaware                                          | 001-36845                   |
| (State or Other Jurisdiction of<br>Incorporation) | (Commission<br>File Number) |

47-3116175  
(IRS Employer  
Identification No.)

|                                          |            |
|------------------------------------------|------------|
| 184 Liberty Corner Road, Suite 302       | 07059      |
| Warren, New Jersey                       |            |
| (Address of Principal Executive Offices) | (Zip Code) |

Registrant's telephone number, including area code: (908) 574-4770

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On March 21, 2016, Bellerophon Therapeutics, Inc. issued a press release announcing its financial and operational results for the year ended December 31, 2015. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press Release dated March 21, 2016.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BELLEROPHON THERAPEUTICS, INC.

Date: March 21, 2016

By: /s/ Jonathan M. Peacock  
Name: Jonathan M. Peacock  
Title: Chairman, President and Chief Executive Officer

EXHIBIT INDEX

| Exhibit<br>No. | Description                                                                            |
|----------------|----------------------------------------------------------------------------------------|
| 99.1           | Press Release dated March 21, 2016 (furnished and not filed for purposes of Item 2.02) |